Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.

摘要: Ceftazidime was used as the only intravenous agent for treating lower respiratory tract infections in patients with cystic fibrosis. The risks of inducing beta lactamases and conferring antibiotic resistance are high when monotherapy is used; so emergence resistant bacteria studied prospectively sputum 120 patients. mean age 9.0 (range 0.3-25) years there were equal number male female Pseudomonas aeruginosa ceftazidime bacterium to be isolated from tract, identified chronically colonised occurred 103 (14%) 750 P isolates, 16 36 organisms faeces 17 64 investigated. Eighty two per cent faecal single isolates: same organism successive samples In no case enteric isolate that sputum. Patients by did not harbour any more than non-colonised use a chest exacerbations fibrosis does induce reservoir bacteria.